INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Replimune and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Replimune securities during the Class Period have until September 22, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: FDA Response and Stock Impact - On July 22, 2025, Replimune announced that the FDA issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for RP1 in combination with nivolumab for advanced melanoma treatment [3]. - The CRL indicated that the FDA could not approve the application in its current form, citing inadequacies in the IGNYTE trial and issues related to the confirmatory trial study design [3]. - Following this announcement, Replimune's stock price fell by $9.52 per share, or 77.24%, closing at $2.81 per share on July 22, 2025 [3].